Under contract with researchers from both UCLA* and the University of Illinois College of Medicine Chicago, Campaign 250 will conduct Whole-Exome genetic testing on up to 250,000 patients who have received a positive FM/a® fibromyalgia diagnosis. Once an individual receives a positive FM/a® Test result, they will be invited to take part in the study.
We will perform a Whole-Exome analysis of FM/a® Test positive individuals who will sign a Institutional Review Board (IRB) approved consent and provide a related blood specimen of under one-half ounce. Whole-Exome sequencing looks at the DNA sequence of every exon in an individual’s genes. This type of sequencing allows scientists to compare the DNA of a person who has fibromyalgia-related medical issues to the DNA of healthy individuals. This process can identify mutations that may lead to a specific medical condition—uncovering the genetic basis of medical disorders—such as fibromyalgia.
* UCLA has been contracted to sequence the exomes of research subjects